• Nuvalent plans to present pivotal clinical trial data at the 2026 ASCO Annual Meeting.
• The presentations include neladalkib data in ALK-positive NSCLC that supported a recent FDA NDA submission and an ongoing Phase 3 trial.
• The company will also share the first clinical look at zidesamtinib in ROS1-positive solid tumors, including early response data.

Nuvalent (NasdaqGS:NUVL) is drawing attention ahead of ASCO 2026 as it prepares to showcase data that underpin a recent FDA NDA filing for neladalkib in ALK-positive NSCLC. The stock trades at $101.24, with a return of 38.2% over the past year and a very large gain, about 7x, over the past three years. This highlights how closely investors have been watching the clinical story. These upcoming data readouts add new context for anyone tracking how much of that performance is tied to pipeline progress.

For current and prospective shareholders, the ASCO presentations offer a fresh data point on both Nuvalent's lead program and its earlier stage zidesamtinib effort in ROS1-positive tumors. The results may help clarify how the company’s pipeline breadth and clinical outcomes could influence its position in targeted oncology over time.

Stay updated on the most important news stories for Nuvalent by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Nuvalent.

The ASCO 2026 updates give you a clearer sense of where Nuvalent sits in targeted oncology and how its products could translate into future revenue. Neladalkib is further along, with data that supported a recent FDA New Drug Application in ALK-positive non small cell lung cancer and an ongoing Phase 3 ALKAZAR trial. If regulators eventually approve the drug, Nuvalent would be competing in a market that already includes therapies from companies such as Pfizer, Roche and Takeda, so efficacy in TKI pre treated patients and a clean safety profile will matter for share capture and pricing power. The first clinical look at zidesamtinib in ROS1-positive solid tumors, with a 40% objective response rate and generally well tolerated safety, points to an attempt to expand beyond NSCLC into a broader group of ROS1-driven cancers. For a pre revenue company, multiple shots on goal like this can be important, as each indication and line of therapy potentially opens an additional revenue stream and supports the case for partnerships or capital raising, but it also increases the importance of consistent trial execution and regulatory outcomes.

The Risks and Rewards Investors Should Consider

• ⚠️ Nuvalent currently generates less than US$1m in revenue, so the business is heavily dependent on external funding until any products are approved and commercialized.
• ⚠️ The company is unprofitable and analysts do not expect it to reach profitability over the next 3 years, so any trial setbacks or delays could increase financing risk.
• 🎁 ASCO 2026 includes pivotal neladalkib data that supported an FDA NDA and an ongoing Phase 3 trial, which, if successful with regulators, could open a new targeted oncology revenue stream.
• 🎁 Preliminary zidesamtinib data, including a 40% objective response rate in ROS1-positive solid tumors and a generally well tolerated safety profile, points to an additional pipeline asset that may broaden Nuvalent's market opportunity over time.

What To Watch Going Forward

Following this news, it is worth watching how regulators respond to the neladalkib NDA, any updates from the Phase 3 ALKAZAR trial and whether the ASCO data shift expectations around adoption in a field that already includes large players such as Pfizer, Roche and Takeda. For zidesamtinib, further efficacy and durability data in ROS1-positive tumors, plus any move into larger trials, will help you judge whether the early 40% response signal holds up in broader populations. Funding moves, such as partnerships or capital raises following ASCO, will also be important checks on how the market and potential collaborators view the commercial prospects of Nuvalent's pipeline.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Nuvalent, head to the community page for Nuvalent to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.